Search clinical trials for: antibody ch14.18

Total 2498 results

Shanghai Henlius Biotech

Completed

Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor

Adult Solid Tumor

China
ThromboGenics

Completed

A Study to Evaluate the Safety and Efficacy of THR-317 for the Treatment of Diabetic Macular Oedema (DME)

Diabetic Retinopathy | Macular Edema

Czechia, Slovakia, Hungary
Case Comprehensive Cancer Center
Cephalon

Terminated

Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
National Cancer Institute (NCI)

Completed

Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIIB Non-small Cell Lung Cancer | Stage IV Renal Cell Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Recurrent Metastatic Squamous Neck Cancer With... and other conditions

United States
The Second Affiliated Hospital of Chongqing Medical...

Recruiting

The Safety and Tolerability of MY-586 COVID-19 Neutralizing Antibody Nasal Spray in Healthy Subjects

SARS-CoV-2 | Prevention

China
City of Hope Medical Center
National Cancer Institute (NCI); Imugene Limited

Active, not recruiting

CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study

Metastatic Undifferentiated Pleomorphic Sarcoma | Recurrent Undifferentiated Pleomorphic Sarcoma | Locally Advanced Undifferentiated Pleomorphic Sarcoma | Unresectable Undifferentiated Pleomorphic Sarcoma

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer

Prostate Cancer

United States
United BioPharma

Not yet recruiting

Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria

Chronic Idiopathic Urticaria
Odense University Hospital

Recruiting

Effects of Male-specific Antibodies on Sex Ratio

Sperm Antibodies | Sex Ratio

Denmark
Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Completed

to Evaluate the Preliminary Efficacy and Safety of GR1501 Injection in Patients With Active Axial Spondyloarthritis

Axial Spondyloarthritis

China
Institute of Tropical Medicine, Belgium
Institut National de Recherche Biomédicale. Kinshasa, République Démocratique...

Completed

COVID-19 Sero-prevalence Health Care Workers Kinshasa (PRESTACOV)

SARS-CoV Infection | Seroprevalence

Congo, The Democratic Republic of the
Johns Hopkins University
Massachusetts General Hospital; National Institutes of Health (NIH); National...

Terminated

Dietary Interventions in Asthma Treatment: Sprouts Study

Asthma | Allergy

United States
Mansoura University

Unknown

Role of Serum Regucalcin in Diagnosis of Hepatocellular Carcinoma

Role of Serum Regucalcin in Diagnosis of HCC

Egypt
Eli Lilly and Company

Completed

Effect of LY2062430 on the Progression of Alzheimer's Disease (EXPEDITION2)

Alzheimer's Disease

Spain, United States, France, Korea, Republic of, Japan, Australia, Taiwan, Sweden, Germany, Italy, Poland, Russian Federation, United Kingdom
The First Affiliated Hospital of Soochow University
The First Affiliated Hospital with Nanjing Medical University; The Affiliated... and other collaborators

Recruiting

Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement

Safety and Efficacy

China
Sun Yat-sen University
Guangzhou No.12 People's Hospital; Kaiping Central Hospital

Withdrawn

HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC

Hepatocellular Carcinoma

China
Shi Ming

Suspended

Lenvatinib Plus PD-1 Antibody for Unresectable ICC

Intrahepatic Cholangiocarcinoma

China
National Cancer Institute (NCI)

Completed

Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
University of Wisconsin, Madison
National Cancer Institute (NCI); EMD Serono

Completed

Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma

Melanoma

United States
Rockefeller University

Completed

3BNC117 and 10-1074 in HIV Uninfected Adults

Human Immunodeficiency Virus

United States
Ahmad Tarhini
Pfizer

Completed

Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma

Melanoma

United States
University of California, San Francisco
Gilead Sciences

Suspended

Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors (PNOC025)

Brain Cancer | Malignant Brain Tumor | Brain Tumor Adult | Recurrent Brain Tumor | Progressive Malignant Brain Tumor | Brain Tumor, Pediatric

United States
Shanghai Henlius Biotech

Completed

Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2

Solid Tumor

China
Eli Lilly and Company

Completed

Effect of LY2062430 on the Progression of Alzheimer's Disease (EXPEDITION)

Alzheimer's Disease

United States, Argentina, Brazil, Japan, Canada
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health Subjects

Hypercholesterolemia

China
National Cancer Institute (NCI)

Completed

Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only

Recurrent Breast Carcinoma | Invasive Breast Carcinoma | HER2/Neu Positive | Stage IV Breast Cancer AJCC v6 and v7

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific
National Cancer Institute (NCI)

Completed

S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Bronchoalveolar Cell Lung Cancer | Large Cell Lung Cancer | Adenosquamous Cell Lung Cancer

United States
Texas Cardiac Arrhythmia Research Foundation

Recruiting

Immune Response Following COVID-19 Vaccination (IFVAC)

IgM and IgG in Blood

United States
Huabo Biopharm Co., Ltd.

Recruiting

A Study of Injection HB0025 in Patients With Advanced Solid Tumors

Tumor, Subjects

United States, China
Shanghai Huaota Biopharmaceutical Co., Ltd.

Completed

HB0034 in Patients With Generalized Pustular Psoriasis (GPP)

Generalized Pustular Psoriasis

China
David Grant U.S. Air Force Medical Center

Withdrawn

Profiling Spike Protein Antibody Response Post COVID-19 Booster

Spike Protein IgG Antibody | COVID-19 Booster
CSL Behring

Completed

Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects

Healthy

Australia
Shanghai Henlius Biotech
Hengenix Biotech Inc; Sanyou Biopharmaceuticals(Shanghai)Co., Ltd; Shanghai ZJ...

Withdrawn

Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers

COVID-19
St. Jude Children's Research Hospital
University of Wisconsin, Madison; Duke University; Children's Hospital Los Angeles and other collaborators

Completed

A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma

Melanoma | Osteosarcoma | Ewing Sarcoma | Neuroblastoma

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Completed

Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer

Squamous Cell Carcinoma of the Skin | Recurrent Skin Cancer

United States
Xijing Hospital

Not yet recruiting

Clinical Study of 68Ga Labeled HER2 Affibody Analogues

HER2-positive Breast Cancer and Gastric Cancer
Shanghai Henlius Biotech

Not yet recruiting

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors

Solid Tumor, Adult
Sun Yat-sen University

Withdrawn

Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC

Hepatocellular Carcinoma

China
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody F19 in Treating Patients With Advanced or Metastatic Cancer

Colorectal Cancer

United States, Australia
University of Leicester

Unknown

Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma

Neuroblastoma

Ireland, United Kingdom, France, Switzerland, Austria, Italy, Spain, Norway, Belgium, Denmark, Israel, Portugal, Sweden
Stony Brook University

Completed

HSV Seroprevalence and Diagnosis of Genital Herpes in Pregnant Women

Pregnancy

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

Advanced Malignant Solid Neoplasm | Recurrent Breast Carcinoma | Estrogen Receptor Positive | HER2/Neu Positive | Progesterone Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7 | Postmenopausal | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 and other conditions

United States
Sun Yat-sen University
Guangdong Provincial Hospital of Traditional Chinese Medicine; Fujian Cancer... and other collaborators

Recruiting

PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients

Lynch Syndrome

China
Frontier Biotechnologies Inc.

Recruiting

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects (ABL)

HIV-1-infection

United States
RenJi Hospital

Completed

Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma

Neoadjuvant Immunotherapy of Cisplatin-ineligible High Risk Upper Urinary Tract Urothelial Carcinoma

China
AstraZeneca

Completed

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

Melanoma | Neoplasms | Renal Cell Carcinoma | Prostatic Neoplasms | Colorectal Neoplasms | Patients Who Have/Have Had Melanoma and Other Tumors

United States, United Kingdom
Karolinska Institutet
Karolinska University Hospital

Active, not recruiting

Current and Past SARS-CoV-2 Infection and COVID-19 in Healthcare With Regard to Vaccinations

SARS-CoV 2

Sweden
Pfizer

Withdrawn

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer

Poland, United States

Search clinical trials for: antibody ch14.18

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations